Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone)

Journal of the American College of Cardiology

Volumn 53, Issue 22, 2009, Pages 2028-2035

  Lonn, Eva M ^a,b   Gerstein, Hertzel C ^a,b   Sheridan, Patrick ^b   Smith, Sandra ^b   Diaz, Rafael ^c   Mohan, Viswanathan ^d   Bosch, Jackie ^b   Yusuf, Salim ^a,b   Dagenais, Gilles R ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Etudios Cardiologica Latin America Rosario   (Argentina)

^d MADRAS DIABETES RESEARCH FOUNDATION   (India)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

ACE inhibitors; atherosclerosis; carotid intima media thickness; pre diabetes; thiazolidinediones

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

ADULT; ANGINA PECTORIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; FACTORIAL DESIGN; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SIDE EFFECT; STROKE; ULTRASOUND; WEIGHT GAIN;

EID: 65649099695     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.12.072     Document Type: Article

References (29)

1. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
2. Mazzone T., Chait A., and Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371 (2008) 1800-1809
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
4. Dzau V.J., Bernstein K., Celermajer D., et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 16 (2002) 149-160
5. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
6. Lonn E., Yusuf S., Dzavik V., et al., SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
7. Wang J.G., Staessen J.A., Li Y., et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 37 (2006) 1933-1940
8. Henriksen E.J., Jacob S., Kinnick T.R., Youngblood E.B., Schmit M.B., and Dietze G.J. ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 277 (1999) R332-R336
9. Abuissa H., Jones P.G., Marso S.P., and O'Keefe Jr. J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
10. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
11. Brown J.D., and Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115 (2007) 518-533
12. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., and Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 (1998) 1818-1820
13. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
14. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
15. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Circulation 111 (2005) 2525-2531
16. Hodis H.N., Mack W.J., Zheng L., et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 29 (2006) 1545-1553
17. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
18. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
19. Nissen S.E., Nicholls S.J., Wolski K., et al. for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
20. Bosch J., Yusuf S., Gerstein H.C., et al., DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
21. Gerstein H.C., Yusuf S., Bosch J., et al., DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
22. Dagenais G.R., Gerstein H.C., Holman R., et al., DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31 (2008) 1007-1014
23. de Groot E., van Leuven S.I., Duivenvoorden R., et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med 5 (2008) 280-288
24. Bots M.L., Evans G.W., Riley W.A., and Grobbee D.E. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 34 (2003) 2985-2994
25. Zhao S., Zhang C., Lin Y., et al. The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits. Thromb Res 123 (2008) 281-287
26. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized controlled trials. Lancet 370 (2007) 1129-1136
27. Dormandy J.A., Charbonnel B., Eckland D.J., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
28. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
29. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195